Abstract
Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) is a cornerstone for the management of obesity and type 2 diabetes. GLP-1RAs improve the glycemic control by suppressing glucagon secretion and stimulating insulin secretion in patients with type 2 diabetes. Here, we report the case of a patient with type 2 diabetes with postprandial hyperglucagonemia who was successfully treated by the administration of once-weekly dulaglutide. A 67-year-old, non-obese woman was admitted to our hospital for preoperative glycemic control. Her glycemic control significantly improved after the administration of dulaglutide. Both fasting and postprandial plasma glucagon levels were effectively suppressed by dulaglutide, which ameliorated hyperglycemia. Thus, to achieve an optimal glycemic control, clinicians should consider suppressing glucagon secretion in addition to improving insulin secretion and sensitivity. J Endocrinol Metab. 2018;8(1):6-9 doi: https://doi.org/10.14740/jem486w
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
